Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CPN1 | P15169 | 2/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496835 | 0.89 | KDM4E (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL17560474 | 0.87 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL30948839 | 0.87 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL25662164 | 0.83 | CPN1 (0.57) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL25662157 | 0.83 | CPN1 (0.57) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL4189286 | 0.83 | CPN1 (0.57) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL7494708 | 0.81 | CPN1 (0.47) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Zinc Ion SCHEMBL9276168 | 0.80 | CPN1 (0.46) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL21905026 | 0.80 | — | — | |
| SCHEMBL1037019 | 0.79 | CPN1 (0.45) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-105764502-A | Combination methods for improving the therapeutic benefit of bisantrene and analogs and derivatives thereof | 现代化制药公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-105764501-A | Compositions for improving the therapeutic benefit of bisantrene | 现代化制药公司 | 2016-07-13 | — | — | CN | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | KDM4E 1999/4885MAPT 536/4885KMT2A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.